Methylergobrevin en es it fr

Methylergobrevin Brand names, Methylergobrevin Analogs

Methylergobrevin Brand Names Mixture

  • No information avaliable

Methylergobrevin Chemical_Formula


Methylergobrevin RX_link

Methylergobrevin fda sheet

Methylergobrevin msds (material safety sheet)

Methylergobrevin MSDS

Methylergobrevin Synthesis Reference

A. Stoll et al., eidem, Helv. Chim. Acta. 26, 944 (1943)

Methylergobrevin Molecular Weight

339.432 g/mol

Methylergobrevin Melting Point

172 oC

Methylergobrevin H2O Solubility

25 mg/mL

Methylergobrevin State


Methylergobrevin LogP


Methylergobrevin Dosage Forms

Injection (intramuscular or intravenous); Tablet

Methylergobrevin Indication

For the prevention and control of excessive bleeding following vaginal childbirth

Methylergobrevin Pharmacology

Methylergonovine is a semisynthetic ergot alkaloid and a derivative of ergonovine and is used for the prevention and control of postpartum and post-abortion hemorrhage. In general, the effects of all the ergot alkaloids appear to results from their actions as partial agonists or antagonists at adrenergic, dopaminergic, and tryptaminergic receptors. The spectrum of effects depends on the agent, dosage, species, tissue, and experimental or physiological conditions. All of the alkaloids of ergot significantly increase the motor activity of the uterus. After small doses contractions are increased in force or frequency, or both, but are followed by a normal degree of relaxation. As the dose is increased, contractions become more forceful and prolonged, resting tonus is markedly increased, and sustained contracture can result.

Methylergobrevin Absorption

Absorption is rapid after oral (60% bioavailability) and intramuscular (78% bioavailability) administration.

Methylergobrevin side effects and Toxicity

Signs and symptoms of overexposure: hypertension, seizures, headache, hypotension, nausea, and vomiting.

Methylergobrevin Patient Information

Methylergobrevin Organisms Affected

Humans and other mammals